A new once-daily, fixed-dose eye drop–Rocklatan (combination netarsudil and latanoprost)–has shown efficacy in treating open-angle glaucoma and ocular hypertension. The results come from the 3-month randomized, double-masked MERCURY 1 trial.
The trial compared Rocklatan’s efficacy against monotherapy with netarsudil or latanoprost alone in adult patients with primary open-angle glaucoma or ocular hypertension.
Netarsudil may lower intraocular pressure (IOP) through increasing trabecular outflow, decreasing aqueous production, and reducing episcleral venous pressure. Prostaglandin reduces IOP through increasing uveoscleral outflow. Because of this, researchers believed a netarsudil and latanoprost combination would produce a greater reduction in IOP.
Results showed that Rocklatan reduced IOP 1.3-3.0 mm Hg more than netarsudil or latanoprost alone. In addition, a statistically significantly higher proportion of patients achieved diurnal IOP < 15 mm Hg with Rocklatan than monotherapy.
Future studies are needed to examine the efficacy of netarsudil in combination with other medications for other types of glaucoma.
You can read more here.